Ubrogepant

Ubrelvy (ubrogepant) is a small molecule pharmaceutical. Ubrogepant was first approved as Ubrelvy on 2019-12-23. It is used to treat migraine disorders, migraine with aura, and migraine without aura in the USA. It is known to target calcitonin gene-related peptide type 1 receptor. Ubrelvy's patents are valid until 2035-01-30 (FDA).